Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pneumococcal booster vaccine responsiveness to PCV20 in persons of 78-84 years of age (VIVO-2)
2025-521616-19-00Phase 4Authorised
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Jul 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Prevnar 20 in pneumococcal disease, sponsored by National Institute for Public Health and the Environment. Primary endpoint: PCV20 specific serum IgG, IgM and IgA concentrations pre-PCV20 and 1 month post-PCV20 vaccination. Planned start Jul 2025; status: authorised.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2025-521616-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521616-19-00.